Clearwave Corporation

Clearwave Corporation is the leading provider of self-service kiosk registration and insurance verification solutions. Clearwave’s technology dramatically reduces the time patients spend checking in by allowing patients to enter their own data. The kiosk then automatically validates the patient’s insurance—in real time—collects copays and outstanding balances, and handles most of the paper associated with HIPAA consent forms and meaningful use questions. Beyond these great efficiencies, practices can build revenue by using the kiosks to engage patients with questions about direct-pay services such as LASIK, premium IOLs, and other services.

IROC Science, AG

Visit IROC Science at ESCRS 2015, Barcelona, Spain, 5-9 Sept, Hall 8.1 Booth M14. Click here to view the Exhibit Hall map.

Zurich, Switerland-based IROC Science, AG, specializes in providing consulting services for translational research in ophthalmology. Its team of world renowned researchers create value for the ophthalmic industry and clinicians through applied research, product development and clinical trial services. Founded by Prof. Dr. Michael Mrochen IROC Science focuses on medical devices in the field of vision, light and optics. Since 2000, Prof. Mrochen has also served as co-founder of the International Congress of Wavefront Sensing, and since 2004, as a co-founder of the International Congress of Corneal Cross Linking. He was awarded both the Troutman Award from the International Society of Refractive Surgery in 2003, and the Swiss Technology Award for the development of customized contact lenses in 2005.


Everseat is a web and mobile app that helps patients book healthcare appointments. Unfilled appointment slots mean lost revenue for doctors and lost opportunities for patients. By building a two-sided (doctor and patient) market, Everseat is able to match supply and demand in real time.

When providers have cancellations or open slots, they post the available appointment to their Everseat online dashboard. The opening is then immediately offered to interested patients, who can simply click a button to “grab the seat.” The office administrator then confirms the transaction, and the booking is completed within minutes.  

Everseat is revolutionizing how healthcare professionals fill cancelled appointments and excess slots and improving the patient experience along the way. Free to patients, Everseat fosters better communication between providers and patients while saving time and increasing doctors’ profits.


EyeKor, LLC.

EyeKor, LLC., provides access to a coordinated network of established reading centers and clinical trial experts that offers a complete spectrum of integrated ophthalmic clinical trial services. The EXCELSIOR™ software platform is used to harmonize processes between diverse reading centers. EyeKor experts are unified through common standard operating procedures, quality control and assurance, regulatory compliance, and computing infrastructure. The company’s expertise encompasses a diverse array of ophthalmic testing methods that include fundus photography and angiography, optical coherence tomography, fundus autofluorescence imaging, dark adaptation, automated visual field testing, specular microscopy imaging, ocular surface evaluation, and electrophysiological testing.


Phase IV Eyecare Studies

As a result of device malfunctions outside of ophthalmology, new legislation is rapidly moving through the European Parliament that will impose significant new regulatory burdens on device manufacturers. It is expected that these laws will go into effect in 2015. 

These burdens will necessitate ongoing clinical trials beyond those required for CE (Conformité Européenne) marking, which indicates compliance with EU legislation. These post-market studies will entail complexity, cost, and a heavy IT burden in terms of data collection, evaluation, and reporting.

Our collaborative team of IROC Science to Innovation AG, EyeKor, LLC, and Ethis HealthTech, LLC, has a solution specifically engineered to help ophthalmic implantable device manufacturers meet the upcoming European Union (EU) requirements for ongoing phase iv post-market surveillance studies.